Status:
COMPLETED
Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease
Lead Sponsor:
Amgen
Conditions:
Idiopathic Parkinson's Disease
Eligibility:
All Genders
35-70 years
Phase:
PHASE1
Brief Summary
This randomized study was designed to evaluate the efficacy and safety of IPu-infused liatermin (15mg/putamen/day) compared with placebo in subjects with symptomatic, levodopa-response Parkinson's dis...
Eligibility Criteria
Inclusion
- Inclusion Criteria: - Diagnosis of bilateral, idiopathic Parkinson's disease
Exclusion
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00115427
Start Date
March 1 2003
Last Update
January 11 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.